Is the business good?
How good a business is SNDX?
Syndax Pharmaceuticals, Inc. keeps −103% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−103%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +2.4%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 118%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −4708% |
| FY2021 | 19% |
| FY2024 | −1434% |
| FY2025 | −158% |
Details›
- Operating margin12 months to Q1 2026
- −103%
- Net margin12 months to Q1 2026
- −112%
- R&D as % of revenue
- 118%
- Revenue, trailing twelve months
- $217M
- Net income, trailing twelve months
- −$243M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.